scholarly journals Reproducibility of Ocular Surface Staining in the Assessment of Sjögren Syndrome–Related Keratoconjunctivitis Sicca: Implications on Disease Classification

2019 ◽  
Vol 1 (5) ◽  
pp. 292-302 ◽  
Author(s):  
Astrid Rasmussen ◽  
Donald U. Stone ◽  
C. Erick Kaufman ◽  
Kimberly S. Hefner ◽  
Nicole R. Fram ◽  
...  
Keyword(s):  
Ocular Surface ◽  
Keratoconjunctivitis Sicca ◽  
Sjögren Syndrome ◽  
Disease Classification ◽  
Sjogren Syndrome ◽  
Surface Staining

scholarly journals Tear ATG5 as a Potential Novel Biomarker in the Diagnosis of Sjögren Syndrome

Diagnostics ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 71
Author(s):  
Yong-Soo Byun ◽  
Hyun Jung Lee ◽  
Soojung Shin ◽  
Moon Young Choi ◽  
Hyung-Seung Kim ◽  
...  
Keyword(s):  
Ocular Surface ◽  
Area Under The Curve ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Ocular Surface Disease Index ◽  
Dry Eyes ◽  
Potential Biomarker ◽  
Surface Staining ◽  
Breakup Time

Autophagy has been suggested to have an important role in the pathogenesis of Sjögren syndrome (SS). We previously identified that autophagy related 5 (ATG5) was elevated in the tear and conjunctival epithelial cells of SS dry eyes (DE) compared to non-SS DE. The purpose of this study was to investigate the role of tear ATG5 as a potential biomarker in the diagnosis of SS. To confirm this hypothesis, we evaluated the tear ATG5 concentration, and other ocular tests (Schirmer I, tear breakup time (TBUT), ocular surface staining (OSS) score, ocular surface disease index (OSDI)) in SS and non-DE, and compared their diagnostic performance to discriminate SS from non-SS DE. Tear ATG5 showed the greatest area under the curve (AUC = 0.984; 95% CI, 0.930 to 0.999) among the tests, and a 94.6% sensitivity and 93.6% specificity at a cutoff value of >4.0 ng/mL/μg. Our data demonstrated that tear ATG5 may be helpful as an ocular biomarker to diagnose and assess SS. In the future, the diagnostic power of tear ATG for SS should be validated.

Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome

2021 ◽  
pp. 112067212199268
Author(s):  
Pavly Moawad ◽  
Rehab Shamma ◽  
Dina Hassanein ◽  
Gaafar Ragab ◽  
Omar El Zawahry
Keyword(s):  
Ocular Surface ◽  
Sjögren Syndrome ◽  
The Other ◽  
Controlled Study ◽  
P Value ◽  
Sjogren Syndrome ◽  
Artificial Tears ◽  
Dry Eyes ◽  
Significant Difference ◽  
Surface Staining

Purpose: To compare the effect of topical application of tacrolimus 0.03% eyedrops versus cyclosporine 0.05% in Sjogren syndrome subjects with severe dry eyes. Design: A prospective single-blinded simply randomized controlled study. Methodology: 60 Sjogren patients were randomized into Group A: 30 patients were instructed to put tacrolimus 0.03% eyedrops in one eye for 6 months and placebo eyedrops in the other eye, ( N = 30, 44.9 ± 12.58 years). Group B: 30 patients were instructed to put cyclosporine 0.05% eyedrops in one eye for 6 months and placebo eyedrops in the other eye ( N = 30, 49.4 ± 12.92 years). Main outcome measures: Patients were evaluated at day 0, 90, and 180 for Ocular Surface Disease Index Questionnaire (OSDI), frequency of use of artificial tears, average fluorescein tear break up time (TBUT), ocular surface staining scores, Schirmer I test, meibum quality, and expressibility scores. Results: Upon comparing both eyedrops, the mean value of OSDI decrease was 38.25 ± 18.29% versus 31.69 ± 18.57% ( p-value 0.09), SICCA score decrease was 2.97 ± 1.92 versus 2.27 ± 2.02 ( p-value 0.124) the decrease in artificial tear substitute use was 3.90 ± 2.22 versus 3.63 ± 1.92 ( p-value 0.616), increase in Schirmer I values were 4.10 ± 4.21 and 4.26 ± 2.00 ( p-value 0.590) in eyes treated with tacrolimus and cyclosporine respectively. Neither of them affected meibum quality or expressibility scores. Conclusion: Both tacrolimus and cyclosporine significantly improved patient symptoms, frequency of artificial tears use and ocular surface staining compared to placebo-controlled eyes. However, no significant difference regarding the efficacy of both eyedrops at the end of 6 months treatment of severe dry eyes of Sjögren syndrome patients. Trial registration: ClinicalTrials.gov. Identifier: NCT03865888.

MUC19 expression in human ocular surface and lacrimal gland and its alteration in Sjögren syndrome patients

2008 ◽  
Vol 86 (2) ◽  
pp. 403-411 ◽  
Author(s):  
D.F. Yu ◽  
Y. Chen ◽  
J.M. Han ◽  
H. Zhang ◽  
X.P. Chen ◽  
...  
Keyword(s):  
Lacrimal Gland ◽  
Ocular Surface ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome

scholarly journals Tear Proteomics Approach to Monitoring Sjögren Syndrome or Dry Eye Disease

2019 ◽  
Vol 20 (8) ◽  
pp. 1932 ◽  
Author(s):  
Ming-Tse Kuo ◽  
Po-Chiung Fang ◽  
Tsai-Ling Chao ◽  
Alexander Chen ◽  
Yu-Hsuan Lai ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Concentration Ratio ◽  
Sjögren Syndrome ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Sjogren Syndrome ◽  
Tear Proteins ◽  
Proteomics Approach ◽  
Clinical Indices

Sjögren syndrome (SS) or dry eye disease (DED) is one of the most complicated ocular surface diseases. The goal of this study is to elucidate the relationship of the changes in clinical indices of tear film (TF) homeostasis with respect to tear components to allow for SS-DED monitoring and avoid stably controlled SS-DED patients from re-entering a vicious cycle. This prospective case-control study compared stable SS-DED patients with non-SS-DED control from several aspects, including clinical indices for TF homeostasis, 2 DED diagnostic biomarkers (MMP-9 and lactoferrin), and the proteome of flush tears. Compared with non-SS-DED controls, stably controlled SS-DED subjects had less tear secretion and higher ocular surface inflammation, a higher concentration ratio of tear MMP-9/lactoferrin, a more diverse tear proteome, and lower spectral intensities of lipocalin-1, lacritin, and prolactin-inducible protein among the abundant tear proteins. For stable SS-DED patients, the concentration ratio of tear MMP-9/lactoferrin and the corrected lipocalin-1 signal was positively correlated with ocular inflammation and TF stability, respectively. MMP-9 released from stressed ocular surface epithelium and lipocalin-1 secreted from the energetic lacrimal gland are two tear biomarkers responding well to TF homeostasis. The tear proteomics approach through flush tears is a promising method for monitoring SS-DED patients with a standardized sampling procedure and lactoferrin-corrected analysis.

scholarly journals The Deterioration of Meibomian Gland Over the Duration of Sjögren Syndrome

2021 ◽  
Author(s):  
Mi Yeon Song ◽  
Sung Rae Noh ◽  
Kook Young Kim ◽  
Kyu Yeon Hwang ◽  
Young A Kwon ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Meibomian Gland ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Strong Positive Correlation ◽  
Surface Parameters ◽  
Standard Patient ◽  
Average Maximum ◽  
Positive Correlations

Abstract Purpose: To investigate the correlation between Sjögren syndrome (SS) duration and ocular surface parameters in patients with SS-related dry eye. Methods: We analyzed 108 eyes of 108 female patients with primary SS-related dry eye. Meibomian gland (MG) dysfunction, MG dropout, lipid layer thickness (LLT), partial and total blinking, and partial blinking rate (PBR) were measured using a LipiView® II ocular surface interferometer (TearScience, Morrisville, NC, USA). All patients underwent rheumatoid serologic tests and ocular surface assessments. The ocular surface assessment included the Standard Patient Evaluation of Eye Dryness (SPEED), Schirmer’s I test, non-invasive tear break-up time, and grading of corneal/conjunctival staining. The correlations between SS duration and MG dropout rates as well as other ocular surface parameters were determined. Results: The mean SS duration was 54.1±41.3 months. There was a strong positive correlation between SS duration and MG dropout (r = 0.766, p < 0.001). The average, maximum, and minimum LLTs showed a weak negative correlation with SS duration (r = -0.310, -0.211, and - 0.304, respectively, p = 0.014, 0.028, and 0.022, respectively) and MG dropout (r = -0.191, -0.326, and -0.299, respectively, p = 0.049, 0.002, and 0.009, respectively). Significant positive correlations were also observed between the SPEED scores and SS duration (r = 0.303, p = 0.042) and MG dropout (r = 0.450, p = 0.029). Conclusions: Longer durations of primary SS-related dry eye were associated with worse MG dysfunction.

scholarly journals Effect of Autologous Serum Eye Drops in Patients with Sjögren Syndrome-related Dry Eye: Clinical and In Vivo Confocal Microscopy Evaluation of the Ocular Surface

In Vivo ◽  
2016 ◽  
Vol 30 (6) ◽  
pp. 931-938 ◽  
Author(s):  
FRANCESCO SEMERARO ◽  
ELIANA FORBICE ◽  
GIUSEPPE NASCIMBENI ◽  
MARCO TAGLIETTI ◽  
VITO ROMANO ◽  
...  
Keyword(s):  
Confocal Microscopy ◽  
Dry Eye ◽  
Ocular Surface ◽  
Sjögren Syndrome ◽  
Autologous Serum ◽  
Sjogren Syndrome ◽  
Eye Drops ◽  
In Vivo Confocal Microscopy ◽  
Serum Eye Drops

Analysis of ocular surface damage and visual impact in patients with primary and secondary Sjögren syndrome

2020 ◽  
Vol 40 (8) ◽  
pp. 1249-1257 ◽  
Author(s):  
Antonio J. Villarreal-Gonzalez ◽  
I. Jocelyn Rivera-Alvarado ◽  
Luis A. Rodriguez-Gutierrez ◽  
Alejandro Rodriguez-Garcia
Keyword(s):  
Ocular Surface ◽  
Surface Damage ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Visual Impact

scholarly journals Effect of Oral Choline Alfoscerate on Patients with Keratoconjunctivitis Sicca

Nutrients ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1526
Author(s):  
Jin Ju Choi ◽  
Jin Sun Hwang ◽  
Young Joo Shin
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Keratoconjunctivitis Sicca ◽  
T Test ◽  
Ocular Surface Disease Index ◽  
Staining Score ◽  
Symptom Frequency ◽  
Surface Staining ◽  
Visual Analog Pain Score ◽  
Paired T Test

Keratoconjunctivitis sicca (KCS) or dry eye is a disease characterized by ocular surface symptoms. This study aimed to investigate the effectiveness of oral choline alfoscerate (CA) administration as a treatment for KCS. The medical records of dry eye patients who were refractory to topical eyedrops and then took oral CA were reviewed. Results of tear break-up time (TBUT), fluorescein ocular surface staining score (FSS), and tear secretion by the Schirmer test (STT) were analyzed. The results of the ocular surface disease index (OSDI), visual analog pain score (VAS), reporting of the severity and frequency of symptoms, and the modified Standardized Patient Evaluation of Eye Dryness (SPEED) questionnaire were also analyzed. The records of 47 patients were analyzed for this study. The mean age was 62.8 ± 9.3 years, and the patients included 9 males and 38 females. TBUT, OSDI, and VAS significantly improved after CA administration compared to before (p < 0.05, paired t-test). After CA administration, symptom frequency and impact on life improved (p < 0.05, paired t-test). No significant change in photophobia or FSS was identified. In conclusion, oral CA administration was effective in improving tear stability and alleviating symptoms of KCS.

Sign in / Sign up

Export Citation Format

Share Document